View More Recent Stories
-
BofA Securities Reiterates Neutral Rating on Charles River Labs (CRL)
-
Charles River Laboratories (CRL) expects 2025 revenue will decline organically in a similar range as estimated in 2024
-
Charles River Labs (CRL) PT Lowered to $197 at Baird
-
Charles River Labs (CRL) PT Raised to $227 at TD Cowen
-
Charles River Labs (CRL) PT Raised to $211 at Baird
-
Charles River Laboratories (CRL) Tops Q3 EPS by 17c, provides guidance
-
Redburn-Atlantic Starts Charles River Labs (CRL) at Sell
-
Evercore ISI Downgrades Charles River Labs (CRL) to In Line
-
Citi Downgrades Charles River Labs (CRL) to Sell
-
Charles River Laboratories (CRL) and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
-
Mizuho Reiterates Neutral Rating on Charles River Labs (CRL)
-
Charles River Laboratories (CRL) and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
-
Charles River Labs (CRL) PT Lowered to $210 at Mizuho
-
Charles River Labs (CRL) PT Lowered to $203 at TD Cowen
-
JPMorgan Downgrades Charles River Labs (CRL) to Neutral
-
Baird Downgrades Charles River Labs (CRL) to Neutral
-
Charles River Laboratories (CRL) Tops Q2 EPS by 40c; lowers guidance
-
Charles River Laboratories (CRL) Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
-
Charles River Laboratories (CRL) and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
-
Life Science Tools & Diagnostics stocks: Q2 earnings preview
-
Charles River Labs (CRL) PT Lowered to $239 at Baird
-
Argus Downgrades Charles River Labs (CRL) to Hold, 'bearish pattern of lower highs and lower lows'
-
Barclays Starts Charles River Labs (CRL) at Equalweight
-
Charles River Labs (CRL) PT Raised to $271 at Baird
